|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 136.10 EUR | +0.37% |
|
-1.09% | +14.37% |
| 02-03 | Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026 | CI |
| 01-29 | Ipsen Nominates Peter Guenter to its Board of Directors, Effective January 28, 2026 | CI |
| Capitalization | 11.17B 13.2B 10.24B 9.7B 18.01B 1,196B 18.83B 119B 47.11B 576B 49.5B 48.48B 2,072B | P/E ratio 2025 * |
15.9x | P/E ratio 2026 * | 15x |
|---|---|---|---|---|---|
| Enterprise value | 10.38B 12.27B 9.52B 9.01B 16.73B 1,111B 17.5B 111B 43.78B 535B 46B 45.05B 1,926B | EV / Sales 2025 * |
2.75x | EV / Sales 2026 * | 2.43x |
| Free-Float |
41.56% | Yield 2025 * |
1.03% | Yield 2026 * | 1.04% |
Last Transcript: Ipsen
| 1 day | +0.37% | ||
| 1 week | -1.09% | ||
| Current month | -1.09% | ||
| 1 month | +11.83% | ||
| 3 months | +9.94% | ||
| 6 months | +27.79% | ||
| Current year | +14.37% |
| 1 week | 133.4 |  | 138 |
| 1 month | 125.9 | | 139.9 |
| Current year | 116 | | 139.9 |
| 1 year | 87.95 | | 139.9 |
| 3 years | 87.95 | | 139.9 |
| 5 years | 65.9 | | 139.9 |
| 10 years | 34.2 | | 155.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 58 | 30/06/2020 |
| Chief Executive Officer | 56 | 31/12/2019 | |
| Chief Tech/Sci/R&D Officer | 59 | 21/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Antoine Flochel
BRD | Director/Board Member | 61 | 29/08/2005 |
| Chairman | 67 | 21/11/2010 | |
Carol Xueref
BRD | Director/Board Member | 69 | 31/05/2012 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +2.57% | 0.43% | 150 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.37% | -1.09% | +11.92% | +38.59% | 13.2B | |
| +3.66% | +2.03% | +20.48% | +211.52% | 947B | |
| +0.93% | +5.61% | +56.73% | +46.87% | 578B | |
| +2.01% | +0.19% | +17.22% | +53.94% | 395B | |
| -0.64% | +1.63% | +23.32% | +25.27% | 367B | |
| +1.82% | +10.57% | +39.70% | +15.38% | 303B | |
| +0.89% | +3.71% | +21.59% | +33.23% | 298B | |
| +0.57% | +4.66% | +23.89% | +51.27% | 295B | |
| +4.49% | +12.41% | +30.93% | +57.51% | 207B | |
| +5.29% | -20.04% | -53.01% | -38.83% | 208B | |
| Average | +1.94% | +1.87% | +19.28% | +49.48% | 361.05B | |
| Weighted average by Cap. | +2.10% | +2.59% | +24.54% | +80.90% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.77B 4.45B 3.45B 3.27B 6.07B 403B 6.35B 40.14B 15.89B 194B 16.7B 16.35B 699B | 3.99B 4.71B 3.66B 3.46B 6.43B 427B 6.72B 42.49B 16.82B 206B 17.67B 17.31B 740B |
| Net income | 706M 834M 647M 613M 1.14B 75.54B 1.19B 7.52B 2.98B 36.36B 3.13B 3.06B 131B | 749M 885M 687M 651M 1.21B 80.21B 1.26B 7.98B 3.16B 38.61B 3.32B 3.25B 139B |
| Net Debt | -791M -935M -725M -687M -1.28B -84.67B -1.33B -8.43B -3.34B -40.76B -3.5B -3.43B -147B | -1.46B -1.73B -1.34B -1.27B -2.36B -157B -2.47B -15.6B -6.18B -75.47B -6.49B -6.36B -272B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/02/26 | 136.10 € | +0.37% | 58,285 |
| 05/02/26 | 135.60 € | -0.88% | 60,409 |
| 04/02/26 | 136.80 € | +0.51% | 66,343 |
| 03/02/26 | 136.10 € | -0.95% | 91,615 |
| 02/02/26 | 137.40 € | -0.15% | 53,136 |
Real-time Euronext Paris, February 06, 2026 at 04:55 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IPN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition